Search

Your search keyword '"Hirakawa, Miharu"' showing total 164 results

Search Constraints

Start Over You searched for: Author "Hirakawa, Miharu" Remove constraint Author: "Hirakawa, Miharu"
164 results on '"Hirakawa, Miharu"'

Search Results

12. Virus Clearance Reduces Bone Fracture in Postmenopausal Women With Osteoporosis and Chronic Liver Disease Caused by Hepatitis C Virus

18. A Matched Case-Controlled Study of 48 and 72 Weeks of Peginterferon Plus Ribavirin Combination Therapy in Patients Infected With HCV Genotype 1b in Japan: Amino Acid Substitutions in HCV Core Region as Predictor of Sustained Virological Response

20. Diabetes enhances hepatocarcinogenesis in noncirrhotic, interferon-treated hepatitis C Patients

21. Relationship between Alcohol Intake and Risk Factors for Metabolic Syndrome in Men

22. Amino Acid Substitution in HCV Core Region and Genetic Variation near the IL28B Gene Affect Viral Dynamics during Telaprevir, Peginterferon and Ribavirin Treatment

23. Amino Acid Substitution in HCV Core/NS5A Region and Genetic Variation Near IL28B Gene Affect Treatment Efficacy to Interferon plus Ribavirin Combination Therapy

24. Clearance of hepatitis B surface antigen during long-term nucleot(s)ide analogues treatment in chronic hepatitis B

25. Effect of early antiviral agent therapy (NS3 and NS5A inhibitors) in chronic hepatitis C null responders

26. Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin

27. Amino acid substitutions in the hepatitis C virus core region of genotype 1b affect very early viral dynamics during treatment with telaprevir, peginterferon, and ribavirin

28. Clinical and virological effects of long-term (over 5 years) lamivudine therapy

29. Relationship between SNPs in the IL28B region and amino acid substitutions in HCV core region in Japanese patients with chronic hepatitis C

30. Efficacy and Safety of Combination Therapy of Natural Human Interferon .BETA. and Ribavirin in Chronic Hepatitis C Patients with Genotype 2 and High Virus Load

31. Efficacy and Safety of Combination Therapy of Natural Human Interferon Beta and Ribavirin in Chronic Hepatitis C Patients with Genotype 1b and High Virus Load

32. Extending Combination Therapy with Peginterferon plus Ribavirin for Genotype 2 Chronic Hepatitis C Virological Responders: A Pilot Study of 7 Cases

33. Transcatheter arterial chemotherapy with miriplatin for patients with hepatocellular carcinoma and Child-Pugh B liver cirrhosis

34. Increase of rtA181T mutant strains during entecavir therapy for a patient with chronic hepatitis B virus infection

35. Sustained virological response in a patient with chronic hepatitis C treated by monotherapy with the NS3-4A protease inhibitor telaprevir

36. The efficacy of virological response in treatment-naïve patients with chronic hepatitis C treated by NS3-4A protease inhibitor (telaprevir) , pegylated interferon and ribavirin for 12 weeks

37. Low hepatitis B virus core-related antigen is a predictor of absence in post-treatment recurrence of hepatocellular carcinoma during antiviral therapy

38. The Efficacy of Interferon-beta Monotherapy for Elderly Patients with Type C Hepatitis of Genotype 2

39. Virological and Biochemical Features in Elderly HCV Patients with Hepatocellular Carcinoma: Amino Acid Substitutions in HCV Core Region as Predictor of Mortality after First Treatment

40. Association of Amino Acid Substitution Pattern in Core Protein of Hepatitis C Virus Genotype 2a High Viral Load and Virological Response to Interferon-Ribavirin Combination Therapy

41. Combination Therapy of Peginterferon and Ribavirin for Chronic Hepatitis C Patients with Genotype 1b and Low-virus Load

42. Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C

43. Efficacy in Patients with Dose Reduction in Combination Therapy of Peginterferon and Ribavirin for Chronic Hepatitis C

44. Hepatitis C virus enhances incidence of idiopathic pulmonary fibrosis

45. Hepatocarcinogenesis Following HCV RNA Eradication by Interferon in Chronic Hepatitis Patients

46. Lipiodol and Dye at the Site of Ablation Decreases during RFA

47. The Efficacy of 24-Week Interferon Monotherapy for Type C Liver Cirrhosis in Japanese Patients with Genotype 1b and Low Virus Load

48. New ablation procedure for a radiofrequency liver tissue coagulation system using an expandable needle

50. Hall Thruster.

Catalog

Books, media, physical & digital resources